Endo Pharmaceuticals 2006 Financial Guidance Conference Call - Abstract.BOSTON -- The Endo Pharmaceuticals Endo became Endo Pharmaceuticals Inc. as a result of a management buyout from DuPont Merck in 1997. Endo is a specialty pharmaceutical company engaged in the research, development, sale and marketing of prescription pharmaceuticals used primarily to treat and manage pain. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ENDP ENDP Ethiopian National Democratic Party ENDP Exception To National Disclosure Policy ) Corporate Conference Call took place on 9-Jan-06 5:00pm ET. Management reported that it expects net sales Net Sales The amount a seller receives from the buyer after costs associated with the sale are deducted. Notes: This amount is calculated by subtracting the following items from gross sales: merchandise returned for credit, allowances for damaged or missing goods, freight for the year ending 12/31/06 to be approx. $860-880m. ENDP estimates adjusted earnings for the year ending 12/31/06 to be approx. $1.75-1.80 per share, which excludes estimated payments to partners for successful achievement of regulatory milestones and excludes stock compensation charges. More information on this Conference Call can be obtained from Research and Markets at http://www.researchandmarkets.com/transcripts/76786 This document provides a non-biased summary of the conference call detailing the key points and the full Q&A session. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion